StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
2661.HK$19.94-17.47%
Fair $19.94+0.0%

2661.HK

QingSong Health Corp

Healthcare / Health Information ServicesHKSE

$19.94

-4.22 (-17.47%)

Fairly Valued+0.0%Fair Value $19.94Fund rank 32/100 · Data gapFallback financials|
SA 34/D
F-Score: 4/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 25% · confianza 25%

FCF escenarios

weak_data · normalized FCF $57.2M · quality 60.0/100

Data gap 32/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 52/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

34/100

D

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

12/100

SEC 0%

Latest source: unknownPeriods: 3Warnings: 1unknown: 3
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -0.9%, below the 5% threshold
Thesis & Journal · 2661.HKLocal privado en este navegador · QingSong Health Corp
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$4.1B

P/E

395.8x

↑

EV/EBITDA

58.2x

↑

ROE

-0.9%

↓

Gross Margin

38.3%

↓

Debt/Equity

-0.00

↓
52-Week Range$20
$20$163

TradingView lightweight chart

2661.HK price, volumen y niveles de valoración

Último $19.94Periodo -66.0%
Fair value: $19.94

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2024 · 2 años de histórico normalizado

Revenue CAGR

+54.9%

FCF CAGR

+20.3%

FCF margin

8.8%

FCF / Net income

7.96x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $945.0M · net income $10.4M · FCF $82.8M

2022-FY → 2024-FY

Gross margin

38.3%-44.3% pts

Operating margin

6.3%-31.0% pts

Net margin

1.1%+1.6% pts

FCF margin

8.8%-5.8% pts
MetricTTM
2024
2023
2022
Income Statement
Revenue$945.0M$945.0M$490.0M$393.6M
Net Income$10.4M$10.4M$73.6M$-2.1M
EBITDA$64.5M$64.5M$147.7M$152.5M
EPS0.050.050.36-0.01
Gross Margin38.3%38.3%79.9%82.6%
Operating Margin6.3%6.3%29.2%37.3%
Net Margin1.1%1.1%15.0%-0.5%
Balance Sheet
Debt/Equity-0.00-0.00-0.00-0.01
Current Ratio6.366.36——
Cash Flow
Free Cash Flow$82.8M$82.8M$7.7M$57.2M
Returns
ROE-0.9%-0.9%-6.1%0.2%
Valuation
P/E395.76395.76——
EV/EBITDA58.1858.18——
Growth & Yield
Revenue Growth92.9%92.9%24.5%—
EPS Growth-85.9%-85.9%3673.2%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

227.5%

muy exigente

EPS terminal req.

$1.77

Spread vs growth

-313.4%

5Y implied EPS CAGR

111.7%

muy exigente

EPS terminal req.

$2.14

Spread vs growth

-197.6%

10Y implied EPS CAGR

52.6%

muy exigente

EPS terminal req.

$3.45

Spread vs growth

-138.5%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total -66.0%

Total return

-66.0%

Start / end P/E

164.5x → 395.8x

EPS bridge

0.36 → 0.05

Residual

-120.7%

EPS growth-85.9%
Multiple rerating+140.6%
Dividend+0.0%
Residual / FX / buybacks / cross-term-120.7%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.